Pilot Study of Bumetanide for Newborn Seizures

Active, not recruiting

Phase 1 Results N/A

Summary of Purpose

The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 10 April 2018.

1 Jan 2010 27 Jan 2009 1 Aug 2018 1 Dec 2018 1 Apr 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator)
  • Purpose: Treatment
  • Endpoint: Pharmacokinetics Study
  • Intervention: Parallel Assignment

Contacts